UCB completed its acquisition of Neurona Therapeutics on 2 June 2026 (announced 17-21 April 2026) for up to $1.15B ($650M upfront + up to $500M milestones), adding lead asset rezanecel (formerly NRTX-1001), a Phase 1/2 allogeneic GABAergic interneuron cell therapy delivered by a single stereotactic hippocampal injection for drug-resistant mesial temporal lobe epilepsy. The deal moves UCB into regenerative medicine atop its long-standing epilepsy franchise (Keppra, Vimpat, Briviact, Fintepla). Rezanecel remains investigational and is not FDA-approved.